Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D)
Ohio State University
44 participants
Feb 25, 2026
INTERVENTIONAL
Conditions
Summary
PRISM-TID is a single center non-inferiority randomized controlled trial of permissive intrapartum glucose management (intervention) versus strict intrapartum glucose management (standard of care) among pregnant individuals with type 1 diabetes (T1D) using hybrid closed loop therapy (HCL) who are admitted for labor management. Participants will be randomized in a 1:1 fashion to one of two intrapartum glycemic control options: permissive (70-140 mg/dL) or strict (70-110 mg/dL). The primary aim of this trial it to demonstrate that permissive intrapartum glucose management is not associated with an increased risk of neonatal dysglycemia compared with strict intrapartum glucose management.
Eligibility
Inclusion Criteria8
- Pregnant individuals
- ≥ 18 years old
- Type 1 diabetes utilizing Hybrid Closed Loop (HCL) therapy
- Intention for vaginal delivery and admitted to Labor and Delivery
- Singleton, non-anomalous fetus
- Gestational age greater than or equal to 35 weeks gestation.
- Cervical dilation is less than 6 cm.
- Delivering at the study institution
Exclusion Criteria7
- Scheduled cesarean delivery
- Cervical dilation ≥ 6 cm on presentation to L\&D
- Receipt of antenatal corticosteroids within 7 days of randomization
- Fetal demise
- Major fetal anomaly (attached)
- Multiple gestation
- Non-English speaking
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will be randomized in a 1:1 fashion to one of two intrapartum glycemic control options: permissive (70-140 mg/dL) or strict (70-110 mg/dL). Participants and clinicians will be unblinded. Once randomized, an order set will be entered into the EMR that will alert pharmacy and nursing colleagues to the appropriate intrapartum glycemic control protocol.
Patients will be asked to wear an optional Continuous Glucose Monitor (CGM) to utilize during labor for research purposes. The CGM will be removed prior to hospital discharge and data will be extracted by trained research personnel. All participants already utilize a CGM device as part of standard of care as part of Hybrid Closed Loop (HCL) therapy. No clinical decisions will be made based upon data from the research CGM device. This data will not be extracted until after hospital discharge.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07293715